Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News
Xconomy
JULY 15, 2016
The week started on a reflective note. And hellos: Third Rock Ventures brought in a well-traveled biotech veteran, Steven Holtzman , to run its hearing-loss startup Decibel Therapeutics. After last week’s revelation of three patient deaths in its leading cancer immunotherapy trial, the FDA suspended the study.
Let's personalize your content